Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin

[1]  Xiaosheng Wang,et al.  Classification of triple-negative breast cancers based on Immunogenomic profiling , 2018, Journal of experimental & clinical cancer research : CR.

[2]  J. Russo,et al.  Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors , 2018, Journal of Experimental & Clinical Cancer Research.

[3]  M. Donadelli,et al.  Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer , 2018, Journal of Experimental & Clinical Cancer Research.

[4]  Ioana Berindan-Neagoe,et al.  The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge , 2018, Journal of breast cancer.

[5]  Anup M Oommen,et al.  Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy , 2018, Nature Communications.

[6]  F. Zhan,et al.  Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma , 2018, The Journal of clinical investigation.

[7]  Han-Xun Wei,et al.  Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer , 2018, International journal of molecular sciences.

[8]  N. Rabaneda-Lombarte,et al.  A C-terminally truncated form of β-catenin acts as a novel regulator of Wnt/β-catenin signaling in planarians , 2017, PLoS genetics.

[9]  A. Bode,et al.  A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo , 2017, EBioMedicine.

[10]  D. Nam,et al.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2 , 2017, The Journal of clinical investigation.

[11]  Yanmei Yang,et al.  Ixazomib enhances parathyroid hormone–induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor , 2017, Molecular biology of the cell.

[12]  Wei Zhang,et al.  Effect of NIMA-related kinase 2B on the sensitivity of breast cancer to paclitaxel in vitro and vivo , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[13]  Ying Zhang,et al.  Endothelial NO Synthase-Dependent S-Nitrosylation of β-Catenin Prevents Its Association with TCF4 and Inhibits Proliferation of Endothelial Cells Stimulated by Wnt3a , 2017, Molecular and Cellular Biology.

[14]  Yan-fen Fang,et al.  Targeting NEK2 as a promising therapeutic approach for cancer treatment , 2016, Cell cycle.

[15]  Lin Zhao,et al.  Lin28A and androgen receptor expression in ER−/Her2+ breast cancer , 2016, Breast Cancer Research and Treatment.

[16]  W. Zhong,et al.  Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer , 2015, BMC Urology.

[17]  N. Ringstad,et al.  Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle , 2015, Nature Communications.

[18]  A. Fry,et al.  Overexpression of the Nek2 kinase in colorectal cancer correlates with beta‐catenin relocalization and shortened cancer‐specific survival , 2014, Journal of surgical oncology.

[19]  W. Nelson,et al.  Nek2 phosphorylates and stabilizes β-catenin at mitotic centrosomes downstream of Plk1 , 2014, Molecular biology of the cell.

[20]  L. Gollahon,et al.  Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells , 2013, Cell cycle.

[21]  S. Agarwal,et al.  Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy , 2013, Journal of experimental & clinical cancer research : CR.

[22]  L. Gollahon,et al.  Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells , 2013, International journal of oncology.

[23]  F. Zhan,et al.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. , 2013, Cancer cell.

[24]  Chi-Ying F. Huang,et al.  Aberrant nuclear localization of EBP50 promotes colorectal carcinogenesis in xenotransplanted mice by modulating TCF-1 and β-catenin interactions. , 2012, The Journal of clinical investigation.

[25]  C. Barisione,et al.  Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. , 2009, American journal of physiology. Heart and circulatory physiology.

[26]  K. Kreuzer,et al.  Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options. , 2009, European journal of cancer.

[27]  S. Ghatak,et al.  Regulation of MDR1 Expression and Drug Resistance by a Positive Feedback Loop Involving Hyaluronan, Phosphoinositide 3-Kinase, and ErbB2*♦ , 2005, Journal of Biological Chemistry.

[28]  G. Mills,et al.  Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling , 2002, Oncogene.

[29]  S. Hirohashi,et al.  Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. , 2000, Cancer research.

[30]  N. Sagata,et al.  Nek2B, a novel maternal form of Nek2 kinase, is essential for the assembly or maintenance of centrosomes in early Xenopus embryos , 2000, The EMBO journal.

[31]  H. Saavedra,et al.  Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. , 2014, Frontiers in bioscience.

[32]  P. Casey,et al.  beta-Catenin is a Nek2 substrate involved in centrosome separation. , 2008, Genes & development.